While phase 3 TRIUMPH trials are outputting positive data, the drug must complete its full testing program and undergo a formal FDA safety and manufacturing review before it hits pharmacy shelves
A list of the names of those directors and executive ocers and a description of their interests in FCAC is contained in the final prospectus for FCAC's initial public oering, which was filed with the SEC on September 23, 2020, and is available free of charge at the SEC's web site at www.sec.gov, or by directing a request to Falcon Capital Acquisition Corp., 660 Madison Avenue, 12th Floor, New York, NY 10065, Attention: Saif Rahman, Chief Financial Ocer
Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Victoza Important Safety Information for Victoza WARNING: RISK OF THYROID C-CELL TUMORS Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice
These findings add to a growing body of anecdotal and pharmacovigilance data suggesting that clinicians and patients should be aware of these unusual neurological reactions
doi:10.1056/NEJMoa1501352 102
J Exp Med 2021 7;218(6):e20201203
